论文部分内容阅读
目的:比较重组人粒细胞集落刺激因子(rhG-CSF)两种不同用法对实体瘤患者化疗后骨髓抑制恢复的影响。方法:选择化疗后曾出现Ⅲ度及Ⅲ度以上骨髓抑制的患者,随机分成A、B两组,分别在化疗结束后第2天开始使用rhG-CSF以及在化疗后白细胞低于2×109/L时开始使用,直至白细胞升至10×109/L。比较两种方法的疗效和用量。结果:血常规检查示两组患者的骨髓功能均能在下一周期化疗前恢复正常,但B组所需rhG-CSF平均3.69支,较A组的6.17支明显减少(P<0.05)。结论:两种方法疗效相当,但所需费用不同,值得临床进一步研究。
OBJECTIVE: To compare the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the recovery of myelosuppression in patients with solid tumors after chemotherapy. Methods: Patients who had grade Ⅲ or higher myelosuppression after chemotherapy were randomly divided into A and B groups. The patients were given rhG-CSF on the second day after the chemotherapy and less than 2 × 109 / L began to use until the white blood cells rose to 10 × 109 / L. Compare the efficacy and dosage of the two methods. Results: The blood tests showed that the bone marrow function of both groups returned to normal before the next cycle of chemotherapy. However, the average number of rhG-CSF in group B was 3.69, which was significantly lower than that in group A (6.17) (P <0.05). Conclusion: The two methods have similar curative effect but different cost, which deserves clinical further study.